Immunooncology: Can the Right Chimeric Antigen Receptors T-Cell Design Be Made to Cure All Types of Cancers and Will It Be Covered?

Table 1

CD-19 designs for leukemia.

	MSKCC	NCI	UPenn
Design	CD28-19-28z	CD28-FMC63-28Z	4-1BB-CD19-BB
Vector	Retrovirus	Retrovirus	Lentivirus
Expression	Approx. 30 days	Approx. 30 days	>4 years
CR in ALL	90%	80%	90%
CR in CLL	0/8		4/14
PR in CLL	0/8		4/14
OOR in CLL	0.00%		57%

CR: complete response, ALL: acute lymphocytic leukemia, CLL: chronic lymphocytic leukemia, PR: partial response, and ORR: overall response rate.